Knack Company Profile

What is the competitive landscape for KNACK

KNACK has six approved drugs.

Summary for Knack

US Patents:	0
Tradenames:	6
Ingredients:	6
NDAs:	6

Drugs and US Patents for Knack

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Knack	ROCURONIUM BROMIDE	rocuronium bromide	INJECTABLE;INJECTION	213476-002	Jan 6, 2026	AP	RX	No	No
Knack	ROCURONIUM BROMIDE	rocuronium bromide	INJECTABLE;INJECTION	213476-001	Jan 6, 2026	AP	RX	No	No
Knack	LEVETIRACETAM	levetiracetam	INJECTABLE;INTRAVENOUS	215465-001	Dec 2, 2025	AP	RX	No	No
Knack	PANTOPRAZOLE SODIUM	pantoprazole sodium	INJECTABLE;INTRAVENOUS	214680-001	May 19, 2022	AP	RX	No	No
Knack	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	213059-002	Feb 15, 2022		DISCN	No	No
Knack	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	216164-001	Jan 29, 2024		DISCN	No	No
Knack	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	216164-002	Jan 29, 2024		DISCN	No	No

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Knack

Last updated: April 23, 2026

Knack: Market Position, Strengths, and Competitive Strategy

What is Knack’s market position in pharmaceuticals?

No reliable, citable information is available in the provided inputs to identify “Knack” as a specific pharmaceutical company, drug brand, active ingredient, or product line, or to map it to an enforceable competitive landscape. Without a defined entity (legal name, country, product INN/brand, and indication), market position cannot be stated in a way that is accurate and decision-grade.

What are Knack’s identifiable strengths?

No reliable, citable information is available to attribute R&D strengths, manufacturing capability, IP position, clinical track record, payer contracts, distribution footprint, or product quality systems to “Knack” in the pharmaceutical context.

Where does Knack sit in the competitive landscape by product and pipeline?

No reliable, citable information is available to:

• identify Knack’s marketed products or indications
• map a pipeline (phase, mechanism, targets, timelines)
• compare it against competitors by efficacy, safety, line of therapy, dosing convenience, or pricing

What patents and regulatory exclusivities shape Knack’s moat?

No reliable, citable information is available to:

• list Knack’s granted patents by jurisdiction and claim scope
• identify regulatory data exclusivity, patent term adjustments, SPCs, or pediatric extensions
• assess freedom-to-operate risk for competitors or license counterparties

What strategic insights follow for investors, BD, and R&D?

No reliable, citable information is available to produce actionable BD or R&D strategy that ties to Knack-specific business realities (asset value drivers, partnerable scopes, or defensible routes to differentiation).

---

Key Takeaways

• Knack’s pharmaceutical competitive landscape cannot be determined from the provided information because the “Knack” entity is not defined and no citable product, company, or IP/regulatory facts are provided.
• No decision-grade conclusions can be produced on market position, strengths, pipeline, pricing power, payer adoption, or defensibility without specific Knack identifiers and sources.

FAQs

1. Is “Knack” a drug brand, a company, or an active ingredient?
   The provided inputs do not define which of these it is in pharmaceuticals.

2. What geography does Knack operate in?
   No geography is provided.

3. Which therapeutic areas does Knack target?
   No therapeutic areas are provided.

4. Does Knack have patent or regulatory exclusivity that blocks competitors?
   No patents or exclusivity records are provided.

5. How does Knack’s product performance compare with peers?
   No products, trials, labels, or endpoints are provided.

---

References

[1]